Type 2 Diabetes, Metformin and Prediabetes: A Results Sheet of What Raises Risk, What Lowers Blood Sugar and What People Search

Abstract A pooled reading of the research, news and search record on type 2 diabetes, laid out as a results sheet. Each result carries a ratio, an interval and a robustness flag. Eight results: 1. Risk. Adiposity 2.17 (95% CI 1.80 to 2.60), insulin resistance 2.10 (95% CI 1.51 to 2.93), blood pressure 1.69 (95% CI 1.37 to 2.08) and liver fat 2.13 (95% CI 1.37 to 3.34) carry the largest ratios for new type 2 diabetes and hold in the more precise half of studies (k = 77, 11, 20, 11; adiposity prediction interval 0.45 to 10.52). 2. Imprecision. Less precise studies report larger ratios: x1.07 per 0.1 standard error for risk factors and x1.20 for diabetes as exposure; the least precise third pools to 2.70 against 1.49 for the most precise. 3. Nulls and failures. Physical activity (0.91, interval up to 1.00), chemicals (1.07) and male sex (1.32) are gone in the precise half; diet quality (0.80 to 1.03) and alcohol include 1.00; prediabetes and cardiovascular events (1.33) is gone in the precise half. 4. Consequences. Type 2 diabetes raises later risk of kidney disease (3.14), cardiovascular events (1.67), death (1.47), dementia (1.42) and cancer (1.57); only kidney disease grows in the precise half. Prediabetes sits below diabetes on all four shared outcomes. 5. Treatment. SGLT2 inhibitors (0.56), GLP-1 agonists (0.65) and metformin (0.79) pair with fewer deaths, all from observational studies; metformin and dementia (1.08) and GLP-1 and cancer (0.97) are nulls. Reviews report an HbA1c fall of 0.28 percentage points (95% CI 0.17 to 0.39), 0.20 in the more precise reviews. 6. Prevalence. Pooled adult diabetes 10.3% (95% CI 9.7 to 10.9; prediction interval 5.4 to 18.9%) and prediabetes 20.0%; studies differ more than regions do. 7. Context: attention. Newer drugs are 5.7 times older drugs in validated news flags and 4.9 times in search, against 0.51 in research; news tracks search month to month only for Ozempic (r = 0.38). 8. Context: counts and growth. 35,903 typed papers name diabetes or prediabetes; the news rate is 1.68 times its 2018-2019 level; the anchor search term is 1.91 times its 2019 level against 1.13 for the control.

Authors

Publication Details

Journal
Research Square
Published
2026-11-17
DOI
https://doi.org/10.21203/rs.3.rs-11753556/v1
Primary Topic
Diabetes, Cardiovascular Risks, and Lipoproteins
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Type 2 Diabetes, Metformin and Prediabetes: A Results Sheet of What Raises Risk, What Lowers Blood Sugar and What People Search

Narendra Kumar
Research Square
Diabetes, Cardiovascular Risks, and Lipoproteins
preprint

Type 2 Diabetes, Metformin and Prediabetes: A Results Sheet of What Raises Risk, What Lowers Blood Sugar and What People Search

Narendra Kumar
preprint en

Abstract

Abstract A pooled reading of the research, news and search record on type 2 diabetes, laid out as a results sheet. Each result carries a ratio, an interval and a robustness flag. Eight results: 1. Risk. Adiposity 2.17 (95% CI 1.80 to 2.60), insulin resistance 2.10 (95% CI 1.51 to 2.93), blood pressure 1.69 (95% CI 1.37 to 2.08) and liver fat 2.13 (95% CI 1.37 to 3.34) carry the largest ratios for new type 2 diabetes and hold in the more precise half of studies (k = 77, 11, 20, 11; adiposity prediction interval 0.45 to 10.52). 2. Imprecision. Less precise studies report larger ratios: x1.07 per 0.1 standard error for risk factors and x1.20 for diabetes as exposure; the least precise third pools to 2.70 against 1.49 for the most precise. 3. Nulls and failures. Physical activity (0.91, interval up to 1.00), chemicals (1.07) and male sex (1.32) are gone in the precise half; diet quality (0.80 to 1.03) and alcohol include 1.00; prediabetes and cardiovascular events (1.33) is gone in the precise half. 4. Consequences. Type 2 diabetes raises later risk of kidney disease (3.14), cardiovascular events (1.67), death (1.47), dementia (1.42) and cancer (1.57); only kidney disease grows in the precise half. Prediabetes sits below diabetes on all four shared outcomes. 5. Treatment. SGLT2 inhibitors (0.56), GLP-1 agonists (0.65) and metformin (0.79) pair with fewer deaths, all from observational studies; metformin and dementia (1.08) and GLP-1 and cancer (0.97) are nulls. Reviews report an HbA1c fall of 0.28 percentage points (95% CI 0.17 to 0.39), 0.20 in the more precise reviews. 6. Prevalence. Pooled adult diabetes 10.3% (95% CI 9.7 to 10.9; prediction interval 5.4 to 18.9%) and prediabetes 20.0%; studies differ more than regions do. 7. Context: attention. Newer drugs are 5.7 times older drugs in validated news flags and 4.9 times in search, against 0.51 in research; news tracks search month to month only for Ozempic (r = 0.38). 8. Context: counts and growth. 35,903 typed papers name diabetes or prediabetes; the news rate is 1.68 times its 2018-2019 level; the anchor search term is 1.91 times its 2019 level against 1.13 for the control.

Research Square
Good health and well-being
Diabetes, Cardiovascular Risks, and Lipoproteins
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon